Cargando…

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

Background: Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2 diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henry, Robert R., Strange, Poul, Zhou, Rong, Pettus, Jeremy, Shi, Leon, Zhuplatov, Sergey B., Mansfield, Traci, Klein, David, Katz, Arie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208164/ https://www.ncbi.nlm.nih.gov/pubmed/30222367 http://dx.doi.org/10.1089/dia.2018.0052

Ejemplares similares

Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial
por: Frías, Juan P., et al.
Publicado: (2016)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz, Stanley S, et al.
Publicado: (2016)

Response to Acute Psychophysical Stress and 24-Hour Glycemic Control in Healthy Older People
por: DiPietro, Loretta, et al.
Publicado: (2012)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

24-Hour Glucose Profiles on Diets Varying in Protein Content and Glycemic Index
por: van Baak, Marleen A.
Publicado: (2014)

Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study
por: Kudo, Akihiro, et al.
Publicado: (2023)

Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial
por: Hao, Zhaohu, et al.
Publicado: (2018)

Sams teach yourself SQL in 24 hours
por: Stephens, Ryan K, et al.
Publicado: (2015)

Sams teach yourself SQL in 24 hours
por: Stephens, Ryan K, et al.
Publicado: (2008)

Sams teach yourself SQL in 24 hours
por: Stephens, Ryan K, et al.
Publicado: (2011)

Cystatin C- and Creatinine-Based Estimates of Glomerular Filtration Rate in Dapagliflozin Phase 3 Clinical Trials
por: Mende, Christian, et al.
Publicado: (2016)

Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus
por: Yoshimura, Yuta, et al.
Publicado: (2023)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Yavin, Yshai, et al.
Publicado: (2016)

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
por: Ferrannini, Ele, et al.
Publicado: (2010)

Hourly measurements not required for safe and effective glycemic control in the critically ill patient
por: Hoekstra, Miriam, et al.
Publicado: (2010)

JavaScript 24-hour trainer
por: McPeak, Jeremy
Publicado: (2011)

Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial
por: Jiang, Lan-lan, et al.
Publicado: (2021)

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
por: Fioretto, Paola, et al.
Publicado: (2016)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus
por: Kong, Sung Hye, et al.
Publicado: (2019)

Patients in 24-hour home care striving for control and safety
por: Swedberg, Lena, et al.
Publicado: (2012)

Effects of reducing free sugars on 24-hour glucose profiles and glycemic variability in subjects without diabetes
por: Pappe, Christina Laeticia, et al.
Publicado: (2023)

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Li, Feng-fei, et al.
Publicado: (2016)

THU244 Clinical Factors Affecting Dapagliflozin Response For Glycemic Control And Body Weight Reduction: Post-hoc Analysis Of BEYOND Study
por: Jeung Ahn, Kyu, et al.
Publicado: (2023)

Importance of Blood Pressure Control Over a 24-Hour Period
por: White, William B.
Publicado: (2007)

Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control
por: Dai, Wenhui, et al.
Publicado: (2022)

Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
por: Lee, Seung-Hwan, et al.
Publicado: (2021)

Characteristics and control of the 24‐hour ambulatory blood pressure in patients with metabolic syndrome
por: Huang, Jian‐Feng, et al.
Publicado: (2021)

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
por: Nauck, Michael A., et al.
Publicado: (2011)

Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
por: Strojek, Krzysztof, et al.
Publicado: (2014)

Arduino programming in 24 hours
por: Blum, Richard
Publicado: (2015)

Joomla!: 24-hour trainer
por: Kramer, Jen
Publicado: (2011)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
por: Bellido, Virginia, et al.
Publicado: (2022)

Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
por: González-Clemente, José M., et al.
Publicado: (2022)

Indication-specific 6-hour systolic blood pressure thresholds can approximate 24-hour determination of blood pressure control
por: Ernst, Michael E., et al.
Publicado: (2010)

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
por: Kohan, Donald E, et al.
Publicado: (2014)

Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone
por: Sathyan, Gayatri, et al.
Publicado: (2007)

Poor glycemic control in workers with diabetes mellitus in relation to long working hours: a cross-sectional study
por: LEE, Jongin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4l5cgcahsnc2mk8tjiquv715nm